Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified pati...

Full description

Bibliographic Details
Main Authors: Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, Clarisse Audigier-Valette, Lionel Uwer, José Hureaux, Denis Moro-Sibilot, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto, Pierre-Jean Souquet, Valérie Gounant, Patrick Merle, Olivier Molinier, Aldo Renault, Audrey Rabeau, Franck Morin, Marc G Denis, Jean-Louis Pujol
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Clinical Medicine
Subjects:
SCLC
ctDNA
atezolizumab
mutation
<i>TP53</i>
<i>RB1</i>
Online Access:https://www.mdpi.com/2077-0383/9/12/3861

Internet

https://www.mdpi.com/2077-0383/9/12/3861

Similar Items